adobe stock photos - Wang Dan French biotech Ciloa SAS has received a €6.5m grant to advance its adiponectin-loaded exosome candidate, APN-sEV, into Phase I safety trials, ahead of efficacy evaluation in indications including type 2 diabetes, obesity, and liver fibrosis.
ADVERTISEMENT